Aevi Genomic Medicine, Llc, A Cerecor Company

This early-stage study tested a drug called NFC-1 in 30 adolescents aged 12-17 with ADHD who also have specific genetic changes affecting brain receptors. The goal was to check the drug's safety and how the body processes it, while also looking for signs it might reduce ADHD symp…